Terms: = Sarcomas AND MITF, WS2A, ENSG00000187098, 4286 AND Treatment
19 results:
1. Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge.
Natsume T; Yoshida H; Nishikawa T; Kikkawa N; Naka T; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2023 Aug; 31(5):778-784. PubMed ID: 36310451
[TBL] [Abstract] [Full Text] [Related]
2. Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line.
Shi C; Gu Z; Xu S; Ju H; Wu Y; Han Y; Li J; Li C; Wu J; Wang L; Li J; Zhou G; Ye W; Ren G; Zhang Z; Zhou R
Cancer Commun (Lond); 2022 Jul; 42(7):627-647. PubMed ID: 35666052
[TBL] [Abstract] [Full Text] [Related]
3. Targeted Therapy in Melanoma and Mechanisms of Resistance.
Czarnecka AM; Bartnik E; Fiedorowicz M; Rutkowski P
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605090
[TBL] [Abstract] [Full Text] [Related]
4. CD10 and p63 expression in a sarcomatoid undifferentiated melanoma: A cautionary (and molecularly annotated) tale.
Lefferts JA; Loehrer AP; Yan S; Green DC; Deharvengt SJ; LeBlanc RE
J Cutan Pathol; 2020 Jun; 47(6):541-547. PubMed ID: 31943331
[TBL] [Abstract] [Full Text] [Related]
5. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
[TBL] [Abstract] [Full Text] [Related]
6. Primary clear cell sarcoma of the calcaneus : Report of a rare case and review of the literature.
Xu Z; Suo H; Zhang Y; Feng W
Orthopade; 2019 Mar; 48(3):232-238. PubMed ID: 30623235
[TBL] [Abstract] [Full Text] [Related]
7. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract] [Full Text] [Related]
8. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract] [Full Text] [Related]
9. Xp11 Translocation Renal Cell Carcinoma and the Mesenchymal Counterparts: An Evolving Concept with Novel Insights on Clinicopathologic Features, Prognosis, treatment, and Classification.
Wang XT; Xia QY; Zhou XJ; Rao Q
Crit Rev Oncog; 2017; 22(5-6):481-497. PubMed ID: 29604926
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive Analysis of miRNome Alterations in Response to Sorafenib treatment in Colorectal Cancer Cells.
Pehserl AM; Ress AL; Stanzer S; Resel M; Karbiener M; Stadelmeyer E; Stiegelbauer V; Gerger A; Mayr C; Scheideler M; Hutterer GC; Bauernhofer T; Kiesslich T; Pichler M
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916938
[TBL] [Abstract] [Full Text] [Related]
11. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.
Tazzari M; Palassini E; Vergani B; Villa A; Rini F; Negri T; Colombo C; Crippa F; Morosi C; Casali PG; Pilotti S; Stacchiotti S; Rivoltini L; Castelli C
BMC Cancer; 2015 Feb; 15():58. PubMed ID: 25880253
[TBL] [Abstract] [Full Text] [Related]
12. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
Perna D; Karreth FA; Rust AG; Perez-Mancera PA; Rashid M; Iorio F; Alifrangis C; Arends MJ; Bosenberg MW; Bollag G; Tuveson DA; Adams DJ
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):E536-45. PubMed ID: 25624498
[TBL] [Abstract] [Full Text] [Related]
13. Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report.
Wagner BP; Epperla N; Medina-Flores R
Diagn Pathol; 2013 Nov; 8():192. PubMed ID: 24274261
[TBL] [Abstract] [Full Text] [Related]
14. EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice.
Yamada K; Ohno T; Aoki H; Semi K; Watanabe A; Moritake H; Shiozawa S; Kunisada T; Kobayashi Y; Toguchida J; Shimizu K; Hara A; Yamada Y
J Clin Invest; 2013 Feb; 123(2):600-10. PubMed ID: 23281395
[TBL] [Abstract] [Full Text] [Related]
15. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
[TBL] [Abstract] [Full Text] [Related]
16. mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma.
Wang Y; Radfar S; Liu S; Riker AI; Khong HT
BMC Med; 2010 Feb; 8():14. PubMed ID: 20163701
[TBL] [Abstract] [Full Text] [Related]
17. Melanocytes and the microphthalmia transcription factor network.
Steingrímsson E; Copeland NG; Jenkins NA
Annu Rev Genet; 2004; 38():365-411. PubMed ID: 15568981
[TBL] [Abstract] [Full Text] [Related]
18. Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases.
Gupta D; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2004 Jun; 28(6):771-80. PubMed ID: 15166669
[TBL] [Abstract] [Full Text] [Related]
19. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling.
Segal NH; Pavlidis P; Noble WS; Antonescu CR; Viale A; Wesley UV; Busam K; Gallardo H; DeSantis D; Brennan MF; Cordon-Cardo C; Wolchok JD; Houghton AN
J Clin Oncol; 2003 May; 21(9):1775-81. PubMed ID: 12721254
[TBL] [Abstract] [Full Text] [Related]
